S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

DiaMedica Therapeutics Stock Forecast, Price & News

+0.05 (+2.48%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
23,266 shs
Average Volume
59,797 shs
Market Capitalization
$54.74 million
P/E Ratio
Dividend Yield
Price Target

DiaMedica Therapeutics Stock Forecast (MarketRank)

Analyst Rating
3.00 Rating Score
1,059.4% Upside
$24.00 Price Target
Short Interest
0.29% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.82 out of 5 stars

Medical Sector

722nd out of 1,428 stocks

Pharmaceutical Preparations Industry

355th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive DMAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DiaMedica Therapeutics logo

About DiaMedica Therapeutics (NASDAQ:DMAC)

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DMAC Stock News Headlines

DiaMedica Therapeutics appoints chief medical officer
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
$-13.59 million
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.67 per share


Free Float
Market Cap
$54.74 million
Not Optionable

DiaMedica Therapeutics Frequently Asked Questions

Should I buy or sell DiaMedica Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DiaMedica Therapeutics stock.
View analyst ratings for DiaMedica Therapeutics
or view top-rated stocks.

What is DiaMedica Therapeutics' stock price forecast for 2022?

1 brokerages have issued twelve-month price targets for DiaMedica Therapeutics' shares. Their DMAC stock forecasts range from $24.00 to $24.00. On average, they predict DiaMedica Therapeutics' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 1,059.4% from the stock's current price.
View analysts' price targets for DiaMedica Therapeutics
or view top-rated stocks among Wall Street analysts.

How has DiaMedica Therapeutics' stock performed in 2022?

DiaMedica Therapeutics' stock was trading at $3.73 at the beginning of 2022. Since then, DMAC stock has decreased by 44.5% and is now trading at $2.07.
View the best growth stocks for 2022 here

When is DiaMedica Therapeutics' next earnings date?

DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for DiaMedica Therapeutics

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) released its earnings results on Wednesday, May, 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.07. During the same quarter in the prior year, the company posted ($0.19) EPS.
View DiaMedica Therapeutics' earnings history

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the following people:
  • Mr. Dietrich John Pauls MBA, Pres, CEO & Director (Age 51, Pay $684.09k) (LinkedIn Profile)
  • Mr. Scott B. Kellen C.A., CFO & Company Sec. (Age 57, Pay $391.72k)
  • Dr. Harry W. Alcorn Jr., Pharm.D., Sr. VP of Clinical Operations (Age 66, Pay $390.27k) (LinkedIn Profile)
  • Dr. Edward G. Calamai Ph.D., Consulting Head of Manufacturing
  • Dr. Kirsten L. Gruis M.D., M.S., Chief Medical Officer (Age 49)
  • Mr. Dominic R. Cundari, Chief Commercial Officer (Age 71)

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE).

When did DiaMedica Therapeutics IPO?

(DMAC) raised $18 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DiaMedica Therapeutics' stock price today?

One share of DMAC stock can currently be purchased for approximately $2.07.

How much money does DiaMedica Therapeutics make?

DiaMedica Therapeutics (NASDAQ:DMAC) has a market capitalization of $54.74 million. The company earns $-13.59 million in net income (profit) each year or ($0.58) on an earnings per share basis.

How many employees does DiaMedica Therapeutics have?

DiaMedica Therapeutics employs 14 workers across the globe.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The official website for DiaMedica Therapeutics is www.diamedica.com. The company can be reached via phone at (763) 312-6755 or via email at skellen@diamedica.com.

This page (NASDAQ:DMAC) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.